Hormone replacement therapy and risk of epithelial ovarian cancer

Purdie, D. M.; Bain, C. J.; Siskind, Victor; Russell, Peter; Hacker, Neville F.; Ward, Bruce G.; Quin, M. A.; Green, A. C.

doi:10.3109/13697139909038090

Cited by 13 publications

(35 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is uncertain whether this association is correlated with the absence of estrogen receptor-α and progesterone receptor expression among most CCC types (19,29,30). In addition, the risk associated with ERT is much larger in women with an intact genital tract than in those with a history of either hysterectomy or tubal ligation (28).…”

Section: Risk Factorsmentioning

confidence: 87%

“…However, some reports showed that ever-use of non-contraceptive hormones or estrogens is associated with increased risk of CCC (19). Furthermore, post-menopausal ERT may be a risk factor associated with both CCC and EAC (28). EACs are related to pregnancy and tubal ligation, while CCCs are the only type associated with non-contraceptive hormone use (19).…”

Section: Risk Factorsmentioning

confidence: 99%

See 1 more Smart Citation

Molecular genetics and epidemiology of epithelial ovarian cancer (Review)

Shoji

Furukawa²,

Yoshizawa³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

show abstract

Section: Risk Factorsmentioning

confidence: 87%

Section: Risk Factorsmentioning

confidence: 99%

Molecular genetics and epidemiology of epithelial ovarian cancer (Review)

Shoji

Furukawa²,

Yoshizawa³

et al. 2011

Oncol Rep

View full text Add to dashboard Cite

show abstract

“…Results from studies conducted in the U.S. [5,11,[13][14][15]31,32], Australia [33], Norway [8], Sweden [29], and U.K [7] have been inconclusive regarding the relationship between EP and ovarian cancer. Overall, we detected no associations with EP use.…”

Section: Discussionmentioning

confidence: 99%

“…Overall, we detected no associations with EP use. Likewise, many observational studies have not supported an association [5,11,15,29,31,33]. Two large cohort studies and one randomized controlled trial have suggested an increased risk of 50% in association with EP use [8,13,14].…”

Section: Discussionmentioning

confidence: 99%

Hormone therapy and ovarian cancer: incidence and survival

Wernli

Newcomb

Hampton

et al. 2008

Cancer Causes Control

View full text Add to dashboard Cite

Objective-We conducted a population-based case-control study to investigate the association between hormone therapy (HT) and ovarian cancer incidence, and followed all these cancer cases to determine the association of HT use with ovarian cancer mortality.Methods-Seven hundred fifty-one incident cases of invasive epithelial ovarian cancer aged 40-79 years were diagnosed in Wisconsin and Massachusetts between 1993-1995 and matched to similarly-aged controls (n=5808). Study subjects were interviewed by telephone, which ascertained information on HT use and specific preparation, estrogen alone (E-alone) or estrogen plus progestin (EP). Ovarian cancer cases were followed-up for mortality through December 2005. Multivariate logistic regression was used to estimate odds ratios and 95% confidence intervals (CI) for ovarian cancer incidence, and Cox proportional hazards modeling was used to estimate hazard ratios and corresponding confidence intervals for ovarian cancer mortality.Results-Ever use of HT was significantly associated with an increased risk of ovarian cancer (odds ratio 1.57, 95% CI 1.31-1.87). The excess risk was confined to women who used E-alone preparations (OR 2.33, 95% CI 1.85-2.95). No significant associations were detected between pre-diagnosis HT use and ovarian cancer survival.Conclusions-Hormone therapy increases risk of ovarian cancer among E-alone users, but there is no substantial impact on survival after diagnosis.

show abstract

“…Fewer studies have examined EPT regimens, and with the exception of the recent Million Women Study (1), those that have are limited by small numbers of cancers or by a low proportion of women who used these products (2)(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15).…”

Section: Introductionmentioning

confidence: 99%

Menopausal Hormone Therapy and Risk of Epithelial Ovarian Cancer

Rossing

Cushing‐Haugen

Wicklund

et al. 2007

Cancer Epidemiology, Biomarkers &Amp; Prevention

104

View full text Add to dashboard Cite

Substantial increase in the use of menopausal hormone therapy (HT) throughout the 1990s, followed by widespread discontinuation after the 2002 publication of the Women's Health Initiative findings, has resulted in large numbers of former HT users among U.S. women. However, few studies have examined whether ovarian cancer risk varies according to recency and duration of specific HT regimens. We assessed risk of epithelial ovarian cancer among users of unopposed estrogen (ET) and combined estrogen/progestogen (EPT). In a population-based study in Washington state, 812 women with ovarian cancer diagnosed in 2002 to 2005 and 1,313 controls were interviewed in person about the use of HT and other characteristics. Women who used a single form of therapy (ET or EPT) were compared with women who never used HT using logistic regression to calculate odds ratios (OR) and 95% confidence intervals (95% CIs). Risk was increased among current or recent (within the last 3 years) users of ET with z5 years of use (ORs, 95% CIs: 1.6, 1.1-2.5 and 1.8, 0.8-3.7, respectively). Little increase in risk was noted among long-term ET users who discontinued use in the more distant past (OR, 1.2; 95% CI, 0.6-2.6). No increase in risk was noted among women who used only EPT, regardless of duration. Compared with women who never used HT, current users of EPT had an OR of 1.1 (95% CI, 0.8-1.5), and risk declined with increasing time since stopping; the OR was 0.7 (95% CI, 0.4-1.0) among women who had discontinued EPT within the last 3 years and 0.5 (95% CI, 0.3-0.7) among women who stopped at an earlier point. Long-term ET may be associated with an increased ovarian cancer risk that wanes after use ceases. We did not observe an increased risk with EPT, and with increasing time after stopping, a reduction in risk became increasingly evident. The progestogen component of HT may confer a risk reduction that is masked by an opposing effect of estrogen until, among former users, estrogenic influences have diminished. These findings, if replicated, may have implications both for public health and development of chemoprevention strategies. (Cancer Epidemiol Biomarkers Prev 2007;16(12):2548 -56)

show abstract

Hormone replacement therapy and risk of epithelial ovarian cancer

Cited by 13 publications

References 0 publications

Molecular genetics and epidemiology of epithelial ovarian cancer (Review)

Molecular genetics and epidemiology of epithelial ovarian cancer (Review)

Hormone therapy and ovarian cancer: incidence and survival

Menopausal Hormone Therapy and Risk of Epithelial Ovarian Cancer

Contact Info

Product

Resources

About